REG - IXICO plc - Contract Win

IXICOAnnouncement

21/07/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220721:nRSU2135Ta&default-theme=true

RNS Number : 2135T  IXICO plc  21 July 2022

IXICO plc

("IXICO" or the "Company")

 

Contract win for a Phase 2 Huntington's disease trial worth circa £2.1m

 

IXICO plc (AIM: IXI), the precision analytics company delivering intelligent
insights in neuroscience, announces that it has once again been selected by a
leading Global Pharma company to support their ongoing drug development
programme in Huntington's disease. HD is a rare, inherited disease that causes
the progressive breakdown of nerve cells in the brain affecting movement, mood
and thinking abilities, leading to irreversible decline and eventual death.

 

This new contract announced today is for IXICO to provide a range of services
to support the phase II dose finding study to explore safety, biomarkers and
efficacy of the investigative drug in over 300 participants with early
manifest and prodromal Huntington's disease. As part of this study, IXICO will
leverage its proprietary and trusted Trial Tracker platform to enable over 70
imaging centres across sixteen countries to upload anonymised patient MRI
scans to IXICO.

 

This new study will focus on a more targeted patient population than in the
previous phase III trial and open-label extension studies, in which the
customer chose to stop dosing patients as a result of an independent
committee's review of the therapy's potential benefit/risk profile for the
study participants.  IXICO's five-year partnership with this sponsor in this
indication, has been critical in the delivery of vital safety monitoring and
efficacy data analysis, enabling the sponsor to develop the new study
protocol.  The clinical programme now continues with this new trial scheduled
to run until end 2024.

 

During the previous pivotal trials, IXICO deployed radiology services and
advanced MRI techniques to enable patient eligibility and safety monitoring
and to improve understanding of the pharmacodynamic aspects of the treatment.
This understanding is now supporting the design, planning and implementation
of further clinical research   focussing on a more targeted patient
population. In addition, IXICO is developing new methods to respond to the
customer's requirements for ever more stringent in-trial patient safety
controls.

 

Having built an extensive portfolio of proprietary imaging data management and
analysis technologies for investigation of neurological disorders since its
inception in 2004, IXICO continues to develop its extensive portfolio of
advanced neuroimaging solutions and services across the entire drug
development lifecycle, from Phase I through to commercialisation.

 

Giulio Cerroni, CEO of IXICO, commented: " We are delighted to continue our
partnership with one of the world's leading pharmaceutical companies working
in the field of neurodegenerative diseases. We have been working closely with
this customer in Huntington's and the broader research community for many
years and continue to play a leading role in leveraging our Neuroimaging
expertise and advanced analytics capabilities for much needed new therapies
for Huntington's disease. This new contract in addition to the recently
announced multi-party consortium for the development of improved imaging
biomarkers for the early detection and staging of Huntington's disease ('HD'),
demonstrates that we continue to build momentum in the adoption of our
advanced analytics and safety monitoring solutions in rare neurological
diseases"

 

 

For further information please contact:

 

 IXICO plc                                         +44 (0)20 3763 7499
 Giulio Cerroni, Chief Executive Officer

 Grant Nash, Chief Financial Officer

 Cenkos Securities PLC (Nominated adviser and sole broker)                         +44 (0)20 7397 8900
 Giles Balleny / Max Gould (Corporate Finance)
 Michael F Johnson / Tamar Cranford-Smith (Sales)

About IXICO

IXICO is dedicated to delivering insights in neuroscience to help transform
the advancement of investigational therapies for neurological diseases, such
as Huntington's, Parkinson's, Alzheimer's disease and Multiple Sclerosis. The
Company's purpose is to advance medicine and human health by turning data into
clinically meaningful information, providing valuable new insights in
neuroscience by supporting pharmaceutical companies across all phases of CNS
clinical research. IXICO's goal is to be a leading advocate of artificial
intelligence in medical image analysis.

 

IXICO has developed and deployed breakthrough machine learning AI data
analytics, at scale, through its remote access TrialTracker technology
platform, to improve the return on investment in drug development and reduce
risk and uncertainty in clinical trials for the Company's pharmaceutical
clients.

 

 

More information is available on www.IXICO.com (http://www.IXICO.com) and
follow us on Twitter @IXICOnews

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  CNTURSWRUNUBUAR